CAMP4 Therapeutics Corporation Increase (Decrease) in Accounts Payable
CAMP4 Therapeutics Corporation (CAMP) reported Increase (Decrease) in Accounts Payable of $911.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-13
- CAMP4 Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $319.00K.
- CAMP4 Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $592.00K, a 238.29% increase year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$467.00K.
- CAMP4 Therapeutics Corporation increase (decrease) in accounts payable for the quarter ending 2025-09-30 was -$546.00K, a 150.42% decline year-over-year.
- CAMP4 Therapeutics Corporation increase (decrease) in accounts payable for fiscal 2025 was -$1.03M, a 711.90% decline from fiscal 2024.
- CAMP4 Therapeutics Corporation increase (decrease) in accounts payable for fiscal 2024 was $168.00K.
- CAMP4 Therapeutics Corporation increase (decrease) in accounts payable for fiscal 2023 was -$1.11M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $319.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $911.00K 10-Q · filed 2026-08-13 | $444.00K derived: sum of 3 quarters · filed 2026-08-13 | -$102.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $592.00K 10-Q · filed 2026-05-07 | $125.00K derived: sum of 2 quarters · filed 2026-05-07 | -$421.00K derived: sum of 3 quarters · filed 2026-05-07 | -$611.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$467.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$1.01M derived: sum of 2 quarters · filed 2026-03-05 | -$1.20M derived: sum of 3 quarters · filed 2026-08-13 | -$1.03M 10-K · filed 2026-03-05 |
| 2025-09-30 | -$546.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$736.00K derived: sum of 2 quarters · filed 2026-08-13 | -$561.00K 10-Q · filed 2025-11-06 | -$1.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$190.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$15.00K 10-Q · filed 2026-08-13 | -$871.00K derived: sum of 3 quarters · filed 2026-08-13 | $212.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $175.00K 10-Q · filed 2026-05-07 | -$681.00K derived: sum of 2 quarters · filed 2026-05-07 | $402.00K derived: sum of 3 quarters · filed 2026-05-07 | -$642.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$856.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $227.00K derived: sum of 2 quarters · filed 2026-03-05 | -$817.00K derived: sum of 3 quarters · filed 2026-03-05 | $168.00K 10-K · filed 2026-03-05 |
| 2024-09-30 | $1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $39.00K derived: sum of 2 quarters · filed 2025-11-06 | $1.02M 10-Q · filed 2025-11-06 | $874.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | -$1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$59.00K 10-Q · filed 2025-08-14 | -$209.00K derived: sum of 3 quarters · filed 2025-08-14 | |
| 2024-03-31 | $985.00K 10-Q · filed 2025-05-13 | $835.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | -$150.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$1.11M 10-K · filed 2025-03-27 | ||
| 2023-09-30 | -$965.00K 10-Q · filed 2024-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |